biotech
biotech Articles
Solid Biosciences Inc. (NASDAQ: SLDB) watched its shares get crushed on Thursday after the company announced some complications with the U.S. Food and Drug Administration (FDA). Specifically, the FDA...
Published:
Last Updated:
A new Merrill Lynch research report makes the case that four top biotech companies the firm covers have some powerful catalysts that could drive performance this year.
Published:
Last Updated:
Proteostasis Therapeutics saw its shares skyrocket going into Tuesday’s session following a pivotal decision from the FDA for the firm’s cystic fibrosis therapy.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Published:
Last Updated:
Global Blood Therapeutics saw its shares pull back on Friday after the firm announced that it would be conducting a secondary offering.
Published:
Last Updated:
Merrill Lynch has taken a look at the biotech industry and made a few picks that could play out in 2018.
Published:
Last Updated:
Vascular Biogenics watched its shares get absolutely crushed on Thursday after the firm reported top-line results for its late-stage trial in patients with recurrent glioblastoma.
Published:
Last Updated:
Dermira watched its shares absolutely collapse early on Monday after the firm reported disappointing results from its late-stage trials in patients with acne vulgaris.
Published:
Last Updated:
Clearside BioMedical saw its shares make an incredible gain to start the week after the firm announced positive topline results from its late-stage trial.
Published:
Last Updated:
24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of March.
Published:
Last Updated:
MannKind Corp. (NASDAQ: MNKD) has been under fire from Wall Street for quite some time and is no stranger to the cold shoulder of analysts. Although, its shares did tumble in Wednesday’s session...
Published:
Last Updated:
Celgene watched its shares drop on Wednesday after the company announced that it received a Refusal to File letter from the FDA.
Published:
Last Updated:
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big...
Published:
Last Updated:
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
Published:
Last Updated:
Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences.
Published:
Last Updated: